mTOR Signaling Pathway in Bone Diseases Associated with Hyperglycemia

Area of Science:

• Endocrinology
• Metabolic Bone Disease
• Molecular Biology

Background:

• Hyperglycemia, a hallmark of diabetes mellitus, is increasingly linked to bone diseases.
• Understanding the molecular underpinnings of hyperglycemia's impact on bone metabolism is crucial due to diabetes' rising prevalence.
• The mammalian target of rapamycin (mTOR) pathway is implicated in cellular processes relevant to bone health.

Purpose of the Study:

• To comprehensively review the role of the mTOR pathway in hyperglycemia-associated bone diseases.
• To synthesize current knowledge on mTOR's influence on bone formation, resorption, inflammation, and vascularity under high-glucose conditions.
• To identify future research avenues for developing mTOR-targeted therapies for diabetic bone complications.

Main Methods:

• Systematic review of basic and clinical research studies.
• Analysis of findings related to mTOR signaling in bone cells and tissues.
• Integration of data on hyperglycemia's effects on bone metabolism via mTOR.

Main Results:

• mTOR signaling is significantly altered in hyperglycemia, affecting bone cell function.
• mTOR dysregulation contributes to impaired bone formation and increased resorption in diabetic conditions.
• mTOR influences inflammatory responses and bone vascularity, exacerbating bone disease in hyperglycemia.

Conclusions:

• The mTOR pathway is a key mediator of hyperglycemia's detrimental effects on bone metabolism.
• Targeting the mTOR pathway holds promise for therapeutic interventions against diabetic bone diseases.
• Further research is needed to fully elucidate mTOR's complex role and optimize therapeutic strategies.